Immunoassay market seen reaching $63.74 billion by 2035

Market Research Future projects the global immunoassay market will grow from $38.10 billion in 2025 to $63.74 billion by 2035, driven by automation, oncology biomarker demand and point-of-care testing. The forecast points to faster adoption of chemiluminescence systems, AI-enabled workflows and decentralized diagnostics across hospitals, labs and home-care settings.

Why it matters: - The immunoassay market is expanding as healthcare systems need faster, more sensitive testing for chronic disease, infectious disease and cancer care. - Growth in automation and near-patient testing could shift more diagnostics out of central labs and into physician offices, retail clinics and home-care workflows. - The market’s projected size, $63.74 billion by 2035, signals sustained demand for reagents, analyzers and software tied to immunoassay platforms.

What happened: - Market Research Future said the global immunoassay market is projected to rise from $38.10 billion in 2025 to $63.74 billion by 2035. - The forecast implies a 5.28% compound annual growth rate from 2026 to 2035. - The release ties the outlook to rising chronic and infectious disease burden, oncology biomarker demand, automation and point-of-care decentralization. - The company also posted a free sample request and a full report page.

The details: - Reagents and kits were the largest product segment in 2025 with a 59.32% share. - Analyzers and instruments were the fastest-growing product segment at a 5.63% CAGR. - Software and services contributed $4.01 billion in 2025. - ELISA held 51.03% of revenue in 2025. - Chemiluminescence immunoassay had the strongest technology growth rate at a 5.70% CAGR. - Rapid tests generated $3.75 billion in 2025. - Infectious diseases were the largest application segment in 2025 with a 32.62% share. - Oncology was the fastest-growing application at a 5.80% CAGR. - Endocrinology accounted for $5.12 billion in 2025. - Blood and serum were the dominant specimen type with a 47.12% share. - Saliva was the fastest-growing specimen class at a 5.52% CAGR. - Urine represented $8.15 billion in 2025. - Hospitals were the largest end-user segment in 2025 with a 33.50% share. - Point-of-care and home-care settings were the fastest-growing end-user segment at a 5.82% CAGR. - Clinical laboratories generated $11.51 billion in 2025. - North America led the market in 2025 with more than 37.90% of global revenue, or about $14.44 billion. - Europe was valued at $10.44 billion in 2025. - Asia-Pacific was the fastest-growing region at a 5.84% CAGR. - South America held about 4.90% of global share. - The Middle East and Africa contributed $1.37 billion in 2025 and grew at a 5.61% CAGR. - Roche Diagnostics held an estimated 17% to 21% revenue share. - Abbott Laboratories held about 13% to 16% share. - Siemens Healthineers held about 10% to 13% share. - Danaher/Beckman Coulter held about 8% to 11% share. - Thermo Fisher Scientific held about 6% to 9% share.

Between the lines: - The report shows immunoassay demand is shifting toward recurring, high-volume testing rather than one-off diagnostics. - Oncology, neurology and chronic-disease monitoring are turning biomarker panels into repeat revenue streams for labs and vendors. - Closed-system instruments paired with matched reagents appear to be reinforcing vendor lock-in and long contract cycles. - AI-enabled autoverification and predictive maintenance are becoming differentiators in large laboratory tenders, not just back-office upgrades.

What's next: - Market Research Future expects growth to continue through 2035 as chronic disease prevalence, companion diagnostics and decentralized testing expand. - Future opportunities highlighted in the release include ruggedized analyzers for emerging markets, blood-based neurodegeneration testing, AI-enabled middleware and reagent-rental contracts. - The market is likely to see more competition around automation, assay menus and workflow integration rather than standalone instrument sales.

The bottom line: - Immunoassay is moving from a mature diagnostics category to a platform business built on automation, recurring consumables and broader clinical use cases.